Redey is neutral about the return of the lipodystrophy project, as it does not affect our base case.
Redeye endorses Iconovo’s new order from a Top-10 pharma company to evaluate a multi-dose inhaler fr...
SRV's net sales in Q4 amounted to EUR 181.8m, below our estimate of EUR 195.
Sjunkande försäljning, men lönsamhetsförbättring att vänta Inför Q4-rapporten har vi justerat ned vå...
Redeye provides its initial take on Vitec’s Q4 2023 report, which came in slightly below our estimat...
Clean EBIT SEK -100m vs. ABGSCe SEK -20m Q1 likely stronger than Q4 Conference call at 12 CET Clean...
Redeye states that sales were higher than estimated and that strong profitability led to adjusted EB...
It was recently reported that Infrahubs had signed an agreement to sell one of its logistics propert...
'24e-'25e EBITDA cut by 9-6% on tough macro Growth somewhat more muted on lighter investments EV/ARR...
Redeye comments on last night’s news that the majority shareholders of Netmore have entered into an ...
Good Q4 to cap great 2023 Concern over longer sales cycles cuts '24e-'25e EBIT by 23%/12% Fair value...
Still high uncertainty, but Elanders is making improvements.
Redeye provides a quick comment after AVTECH’s Q4 2023 preliminary figures release.
Redeye shares its preview of OssDsign’s Q4 2023e results, due on February 6.
Vitrolife will release the Q4 results on 2 February.
All-share bid valued at ~SEK 1.85bn (44% premium) Aros and Besqab are fairly equal in size (mcap, on...
Suominen reports Q4 results on Feb 6. Earnings are to continue their recovery, but the gradient is d...
Adj. EBITA SEK 289m (-3% vs. ABGSCe 299m) Consensus EBITA should not change much 10x 2024e EBITA on ...
Redeye comments on Invisio ahead of its Q4-results (due 13 February) where we expect another quarter...
Ossur reported strong growth and weak margins in Q4 New Medicare reimbursement could have substantia...